In this article, we discuss the 8 latest picks in Harvard University’s stock portfolio. You can skip our detailed analysis of the Harvard Management Company’s history and past performance, and go directly to Harvard University Stock Portfolio: 5 Latest Stock Picks.
Managing the largest academic endowment in the world, valued at $53.2 billion and comprised of over 14,000 funds, the Harvard Management Company has been tasked with the goal to generate strong long-term results to support the educational and research goals of Harvard University since 1974. With a 33.6% return on its investments, the endowment distributed just over $2 billion toward the University’s operating budget, which represented 39% of Harvard’s annual revenue sources.
The fund was managed by Jane Mendillo since July 1, 2008, who served as the President and Chief Executive Officer of the hedge fund till 2014. Graduating from Yale University in 1984, she later earned her M.B.A from the Yale School of Management. Prior to serving as Wellesley College’s Chief Investment Officer since 2002, she served as vice president for external management at Harvard Management Company. Mendillo first joined Harvard Management Company as an equities analyst in 1987, leading to a tenure largely shaped by the financial crisis of 2007–2010. After stepping down from her position, she was replaced by N.P Narvekar in 2016.
As of the third quarter of 2021, the Harvard Management Company manages more than $1.7 billion in its investment portfolio. The primary sectors that the investment firm invests in include technology, healthcare, and financial. Some of the most notable stocks in the fund’s investment portfolio as of the end of Q3 include Apple Inc. (NASDAQ:AAPL), Meta Platforms, Inc. (NASDAQ:FB), Scientific Games Corporation (NASDAQ:SGMS) and Alphabet Inc. (NASDAQ:GOOG).
Our Methodology
Let us now take a look at the 8 latest stock picks Harvard University’s stock portfolio. The Harvard Management Company’s 13F portfolio for the third quarter was used for this analysis. Hedge fund sentiment was derived from Insider Monkey’s database of 867 elite hedge funds.
These are the new stakes of Harvard Management Company, as the firm added these names in its portfolio in the third quarter of 2021.
Harvard University Stock Portfolio: 8 Latest Stock Picks
8. Tenaya Therapeutics, Inc. (NASDAQ:TNYA)
Harvard Management Company’s Stake Value: $13.9 million
Percentage of Harvard Management Company’s 13F Portfolio: 0.81%
Number of Hedge Fund Holders: 11
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) is a California-based preclinical-stage biopharmaceutical company that is focused on discovering, developing, and delivering curative treatments and therapies that address the causes of heart disease.
On October 25, Piper Sandler analyst Yasmeen Rahimi maintained her Overweight rating and $40 price target on Tenaya Therapeutics, Inc. (NASDAQ:TNYA).
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) is a new addition to Harvard Management Company’s Q3 13F portfolio. The fund holds over 673,270 shares of the company worth over $13.9 million. These shares represent 0.81% of the fund’s portfolio value. The company posted an EPS of -$0.68 on November 10, falling short of the estimates by $0.20.
Of the 867 elite funds tracked by Insider Monkey, 11 were long Tenaya Therapeutics, Inc. (NASDAQ:TNYA) at the end of September. Eli Casdin of Casdin Capital is the leading stakeholder of the company.
Similar to Apple Inc. (NASDAQ:AAPL), Meta Platforms, Inc. (NASDAQ:FB), Scientific Games Corporation (NASDAQ:SGMS), and Alphabet Inc. (NASDAQ:GOOG), Tenaya Therapeutics, Inc. (NASDAQ:TNYA) is a notable stock to invest in.
7. Tango Therapeutics, Inc. (NASDAQ:TNGX)
Harvard Management Company’s Stake Value: $9.15 million
Percentage of Harvard Management Company’s 13F Portfolio: 0.53%
Number of Hedge Fund Holders: 18
Tango Therapeutics, Inc. (NASDAQ:TNGX) is a biotechnology and precision oncology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of patients with cancer.
On September 20, SVB Leerink analyst Andrew Berens initiated coverage of Tango Therapeutics, Inc. (NASDAQ:TNGX) with an Outperform rating and $25 price target.
According to Harvard Management Company’s third quarter securities filings, the investment firm holds 708,385 shares of Tango Therapeutics, Inc. (NASDAQ:TNGX), amounting to more than $9.15 million in worth and representing 0.53% of the fund’s investment portfolio. For the third quarter of 2021, Tango Therapeutics, Inc. (NASDAQ:TNGX) reported earnings per share at -$0.28, in line with the estimates for the quarter. The revenue came in at $6.79 million, surpassing market estimates by $380,750.
As of Q3 2021, 18 hedge funds tracked by Insider Monkey reported holding stakes in Tango Therapeutics, Inc. (NASDAQ:TNGX), worth more than $338.6 million.
6. Surrozen, Inc. (NASDAQ:SRZN)
Harvard Management Company’s Stake Value: $5.85 million
Percentage of Harvard Management Company’s 13F Portfolio: 0.34%
Number of Hedge Fund Holders: 18
Surrozen, Inc. (NASDAQ:SRZN) is another California-based preclinical-stage biopharmaceutical company that focuses on the discovery and development of novel regenerative medicines and therapeutics for tissue repair using the specific control of the Wnt signaling pathway.
On October 11, BofA analyst Tazeen Ahmad initiated coverage of Surrozen, Inc. (NASDAQ:SRZN) with a Buy rating and $11 price target. The analyst notes that if successful, Surrozen, Inc. (NASDAQ:SRZN)’s modulating Wnt pathway efforts in tissue regeneration could drive “meaningful upside” to her estimates.
Baker Bros. Advisors is one of the biggest stakeholders of Surrozen, Inc. (NASDAQ:SRZN) as of the end of the third quarter, according to the data tracked by Insider Monkey. Overall, 18 funds were bullish on Surrozen, Inc. (NASDAQ:SRZN) by the end of the September quarter.
Just like Apple Inc. (NASDAQ:AAPL), Meta Platforms, Inc. (NASDAQ:FB), Scientific Games Corporation (NASDAQ:SGMS), and Alphabet Inc. (NASDAQ:GOOG), Surrozen, Inc. (NASDAQ:SRZN) is a stock that investors should take note of.
Click to continue reading and see Harvard University Stock Portfolio: 5 Latest Stock Picks.
Suggested articles:
- 7 Best Stocks and SPACs to Buy Based on Jonathan Esfandi’s JNE Partners’ Latest Portfolio
- 10 Stocks To Invest In According To Stephen Errico’s Locust Wood Capital
- 10 European Stocks to Buy According to Tom Russo’s Hedge Fund
Disclosure: None. Harvard University Stock Portfolio: 8 Latest Stock Picks is originally published on Insider Monkey
